Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System.
10.3343/alm.2018.38.6.569
- Author:
Hye young WANG
1
;
Young UH
;
Seoyong KIM
;
Eunjin CHO
;
Jong Seok LEE
;
Hyeyoung LEE
Author Information
1. Optipharm, Inc., Wonju Eco Environmental Technology Center, Wonju, Korea.
- Publication Type:Original Article
- Keywords:
Mycobacterium tuberculosis complex;
Rifampicin;
Isoniazid;
Drug susceptibility testing;
Quantamatrix Multiplexed Assay Platform
- MeSH:
Biological Assay;
Emergencies;
Isoniazid;
Mass Screening;
Methods;
Mycobacterium tuberculosis*;
Mycobacterium*;
Prevalence;
Public Health;
Rifampin;
Sensitivity and Specificity;
Seoul;
Tuberculosis, Multidrug-Resistant
- From:Annals of Laboratory Medicine
2018;38(6):569-577
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. METHODS: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. RESULTS: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072–0.9888) and 80.0% (72/90; 95% CI 0.7052–0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731–0.8139) and 96.4% (54/56; 95% CI 0.8718–0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282–0.9949) and 99.1% (109/110; 95% CI 0.9453–1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711–1.0000) and INH resistance (124/124; 95% CI 0.9743–1.0000). CONCLUSIONS: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.
